Serotype Distribution in Non-Bacteremic Pneumococcal Pneumonia: Association with Disease Severity and Implications for Pneumococcal Conjugate Vaccines
Open Access
- 23 August 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (8), e72743
- https://doi.org/10.1371/journal.pone.0072743
Abstract
There is limited knowledge of serotypes that cause non-bacteremic pneumococcal pneumonia (NBP). Here we report serotypes, their associated disease potential and coverage of pneumococcal conjugate vaccines (PCV) in adults with NBP and compare these to bacteremic pneumonia (BP). Adults with pneumonia and Streptococcus pneumoniae isolated from the lower respiratory tract or blood were included 1 year in a population-based design in Denmark. Pneumonia was defined as a new infiltrate on chest radiograph in combination with clinical symptoms or elevated white blood count or plasma C-reactive protein. All isolates were serotyped using type-specific pneumococcal rabbit antisera. All values are medians with interquartile ranges. There were 272 cases of NBP and 192 cases of BP. Ninety-nine percent were hospitalized. NBP and BP cases were of comparable age and sex but NBP cases had more respiratory symptoms and less severe disease compared to BP cases. In total, 46 different serotypes were identified. Among NBP cases, 5 serotypes accounted for nearly a third of isolates. PCV10 and -13 types covered 17% (95% confidence interval (CI): 11-23%) and 34% (95% CI: 25-43%) of NBP isolates, respectively. In contrast, the five most frequent serotypes accounted for two-thirds of BP isolates. PCV10 and -13 types covered 39% (95% CI: 30-48%) and 64% (95% CI: 48-79) of BP isolates, respectively. More severe NBP disease was associated with infection with invasive serotypes while there was an inverse relationship for BP. Only a third of cases of adult non-bacteremic pneumococcal pneumonia would potentially be preventable with the use of PCV13 and just one sixth of cases with the use of PCV10 indicating that PCVs with increased valency are needed to increase vaccine coverage for NBP in adults. PCV13 could potentially prevent two-thirds of adult bacteremic pneumococcal pneumonia.Keywords
This publication has 30 references indexed in Scilit:
- Biochemical, Genetic, and Serological Characterization of Two Capsule Subtypes among Streptococcus pneumoniae Serotype 20 StrainsOnline Journal of Public Health Informatics, 2012
- The Danish National Patient RegisterScandinavian Journal of Public Health, 2011
- Test of a Novel Streptococcus pneumoniae Serotype 6C Type Specific Polyclonal Antiserum (Factor Antiserum 6d) and Characterisation of Serotype 6C Isolates in DenmarkBMC Infectious Diseases, 2010
- Association of Serotype with Risk of Death Due to Pneumococcal Pneumonia: A Meta‐AnalysisClinical Infectious Diseases, 2010
- A Trial of a 7-Valent Pneumococcal Conjugate Vaccine in HIV-Infected AdultsThe New England Journal of Medicine, 2010
- Pneumococcal Serotypes and Mortality following Invasive Pneumococcal Disease: A Population-Based Cohort StudyPLoS Medicine, 2009
- New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare qualityThorax, 2009
- An easy method for detection of nasopharyngeal carriage of multiple Streptococcus pneumoniae serotypesJournal of Microbiological Methods, 2008
- Clonal and Capsular Types Decide Whether Pneumococci Will Act as a Primary or Opportunistic PathogenClinical Infectious Diseases, 2006
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987